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Heparin-binding epidermal growth factor-like growth factor in experi-
mental models of membranous and minimal change nephropathy. Hep-
arin-binding epidermal growth factor-like growth factor (HB-EGF) is a
recently described member of the epidermal growth factor (EGF) family.
It binds to heparan sulfate proteoglycans via a cationic domain and is a
potent mitogen for epithelial cells, fibroblasts and vascular smooth muscle
cells. In the present study we have attempted to identify changes in
quantity and distribution of HB-EGF in two models of acute glomerular
epithelial cell injury, using Western blotting, immunohistochemistry and in
situ hybridization. Prior to disease induction, Western blots showed some
expression of HB-EGF protein within glomeruli. Within the first three
days in the acute puromycin aminonucleoside (PAN) and passive Hey-
mann nephritis (PHN) models, immunohistochemistry and in situ hybrid-
ization demonstrated an up-regulation of HB-EGF mRNA and protein in
glomerular epithelial cells (GEC). In both cases, increased protein and
mRNA was found prior to the onset of proteinuria and continued until day
21 post-induction, the last time point studied. Early in the course of the
models, HB-EGF was localized to the cytoplasm of glomerular epithelial
cells. At day 21, however, HB-EGF protein was distributed in a nodular
pattern within GEC and along the glomerular basement membrane
(GBM) in both models, suggesting that the secreted form might bind to
the membrane. The increase in HB-EGF protein within glomeruli was
confirmed by Western blots of glomerular membrane protein which,
however, demonstrated a single 29 kDa species, consistent with the
transmembrane form. These data are not consistent with binding of the
secreted form of HB-EGF to the GBM. The transmembrane form of
HB-EGF is able to signal in a juxtracrine fashion, so increased expression
of HB-EGF mRNA and protein by GEC might contribute to the genesis
of proteinuria through the initiation of abortive GEC mitogenesis.
Several growth factors have been described that bind heparan
sulfate proteoglycans using cationic domains within their amino
acid sequences. Among these are fibroblast growth factors-1 and
-2 (FGF-1 and FGF-2) [1], platelet-derived growth factor (PDGF)
[2], and heparin-binding epidermal growth factor-like growth
factor (HB-EGF) [3–5]. As with other members of the epidermal
growth factor family, HB-EGF is synthesized as a transmembrane
precursor (Fig. 1A) that is cleaved by an unknown protease to
yield the mature protein of 75 to 86 amino acids [6]. The
heparin-binding domain is cationic and predominantly contained
within an N-terminal hydrophilic region in the mature peptide
(Fig. 1B) that is linked to the C-terminal EGF-like domain [4, 7].
Although it has long been known that the glomerular basement
membrane (GBM) is rich in anionic heparan sulfate proteogly-
cans (HSPG) [8–12], there has been little interest in the possibility
that heparin-binding growth factors could bind to the GBM and
alter its function. Heparin-binding growth factors could interfere
with glomerular filtration and lead to proteinuria through the
neutralization of negative charge (although the importance of
charge as a barrier to filtration of macromolecules has recently
been questioned [13]), or alteration of the tertiary structure of the
GBM. Moreover, abortive mitogenesis of glomerular epithelial
cells (GEC) has recently been proposed as a mechanism for loss
of these cells from the surface of the GBM [14], and bare areas of
the GBM have long been known to leak plasma proteins [15, 16].
Since some of these growth factors, including HB-EGF, are
potent epithelial cell mitogens they might stimulate abortive
mitogenesis, thus causing loss of GEC from the GBM, and
proteinuria.
In an earlier study, we reported that HB-EGF mRNA was
up-regulated in visceral glomerular epithelial cells in the Thy 1.1
model of mesangial proliferative glomerulonephritis [17–19]. This
was a surprising finding, because the glomerular mesangial cell
synthesizes HB-EGF following various activating stimuli in vitro
[17–19] and is the primary target of injury in this model. In view
of this unexpected finding in the Thy 1.1 model, we have
attempted to detect HB-EGF mRNA and protein in the acute
puromycin aminonucleoside (PAN) and acute passive Heymann
nephritis (PHN) models of human minimal change disease and
membranous glomerulonephritis, respectively. Both are due to
primary GEC injury and produce significant proteinuria.
METHODS
Experimental models of glomerulonephritis
Passive Heymann nephritis (PHN). Passive Heymann nephritis
was induced according to methods described by Salant and
Cybulsky [20]. Briefly, anti-Fx1A was produced by immunisation
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of sheep with a rat Fx1A preparation. 1 ml of Fx1A (20 mg/ml)
was mixed with an equal volume of complete Freund’s adjuvant
(Sigma Chemical Co., St. Louis, MO, USA) for the first immuni-
zation and incomplete Freund’s adjuvant for all subsequent
immunizations. Immunizations were administered at monthly
intervals for a total of six months. Activity of the antiserum was
assayed by immunodiffusion in agar against Fx1A and by immu-
nohistochemical staining of rat kidney. The antiserum produced
precipitin lines against Fx1A at dilutions of . 1/64 and stained
tubules in rat kidney at dilutions up to 1/10,000. The sheep
antiserum was then heat inactivated, precipitated with 40%
ammonium sulphate, absorbed with rat erythrocytes and rat
serum coupled to Sepharose, dialyzed against 400 volumes of
PBS, and concentrated to 20 mg/ml. 0.6 ml of anti-Fx1A (20
mg/ml) was administered by intravenous injection on two consec-
utive days to 150 to 200 g male Sprague-Dawley rats following
dose finding studies and using a protocol supplied by Dr. David
Salant. Animals were fed on chow and water ad libitum. Urine was
collected in metabolic cages and urinary protein determined using
a modified Lowry assay (BioRad, Hercules, CA, USA). Protein-
uria was detected five days after the first injection (108 6 68 mg/24
hr) and the presence of electron dense deposits confirmed by
electron microscopy. Activity of the antiserum was compared with
that of a known anti-Fx1A antiserum that was a gift of Dr. Salant.
Rats were sacrificed at days 0, 1, 3, 5, 7, 10, 14, 17, and 21 after
induction using intraperitoneal pentobarbital 50 mg/kg to induce
anesthesia. In the intial studies, each group comprised three rats,
but this was subsequently increased to six per group.
Acute puromycin aminonucleoside nephrosis (PAN). Acute pu-
romycin aminonucleoside nephrosis was induced in 150 to 200 g
Sprague-Dawley rats using an established protocol by a single
intravenous injection of 15 mg/100 g puromycin aminonucleoside
(Sigma) [15]. Proteinuria at day 5 post-injection was 284 6 113
mg/24 hr. Rats were sacrificed in groups of three at days 0, 1, 2, 3,
5, 7, 14, and 21. At least six rats were used per group.
Experimental design
Rats with PHN or PAN were sacrificed and both kidneys
removed. Biopsies were obtained for three fixation conditions: (1)
4% paraformaldehyde, (2) 2% glutaraldehyde, and (3) snap
frozen in OCT. The rest of the renal tissue (generally one whole
kidney from each rat) was then used to isolate glomeruli by
differential sieving [21]. Biopsies obtained from three to six rats at
each time point were used for immunohistochemical staining and
in situ hybridization.
Preparation of rabbit anti-HB-EGF polyclonal antibodies
Rabbit anti-HB-EGF antibodies were produced using two
immunizing antigens. Firstly, four New Zealand white rabbits
were immunized subcutaneously with recombinant human HB-
EGF (R&D Systems, Minneapolis, MN, USA), using 5 mg per
immunization mixed with complete Freund’s adjuvant on the first
occasion, and incomplete Freund’s adjuvant on a further three
occasions at four weekly intervals. Following ELISA and immu-
nohistochemical assays of multiple test bleeds, serum from one of
the animals (R847) was incubated at 56°C for 45 minutes to
inactivate complement, diluted in PBS, and affinity purified on a
Protein G Sepharose column (Sigma). The resultant antibody was
concentrated to 1 mg/ml in PBS with Na azide. Secondly, a 24 amino
acid peptide sequence, comprising residues 69-92 of rat HB-EGF
(rHB-EGF69-92; LDLFKVAFSSKPQALATPGKEKNG) [22] was
synthesized and coupled to keyhole limpet hemocyanin (KLH) and,
separately, ovalbumin (OVA) via a C-terminal GGC tag by Dr.
John Fecondo at Swinburne University, Victoria, Australia. Four
New Zealand White rabbits were immunized on one occasion with
5 mg of KLH-coupled peptide in complete Freund’s adjuvant,
followed by three further immunizations of peptide coupled to
OVA in incomplete Freund’s adjuvant at monthly intervals,
following a protocol described by van Adelsberg and Frank [23].
Following ELISA and immunohistochemical assays of multiple
test bleeds, serum from one of the animals (R866) was incubated
at 56°C for 45 minutes to inactivate complement and used as a
diluted antiserum in further studies.
Antibody characterization using Western blotting
Serum from the four rabbits in the two immunization groups
was assayed repeatedly against normal rat kidney sections and
sections from rats with passive Heymann nephritis. Only one in
each group showed any immunohistochemical reactivity (R847
and R866), and these were the only sera to show reactivity against
the immunizing antigen in ELISA. The specificity of both anti-
bodies was confirmed by Western blotting, using rat kidney and
mesangial cell lysates, and recombinant human HB-EGF blotted
onto nitrocellulose membranes. Briefly, cytoplasmic fractions of
rat kidney or confluent rat mesangial cells were used. Mesangial
cells were lysed in reducing SDS-PAGE sample buffer. Rat
kidneys were homogenized in 3 ml homogenization buffer (50 mM
Tris-HCl pH 8.5, 250 mM sucrose, 5 mM pyrophosphate, 50 mM
sodium fluoride, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 1 mM
benzamidine, 0.2 mM phenylmethylsulfonylfluoride) with a glass/
Fig. 1. Structure of HB-EGF. (A) Structure of the transmembrane form
of HB-EGF. The mature peptide comprises a hydrophilic domain and an
EGF-like domain. The hydrophilic domain contains the cationic (basic)
sequences which mediate specific interaction with heparin and heparan
sulfate proteoglycans. (B) Amino acid sequence of the cationic domain of
HB-EGF compared with amphiregulin (AR), betacellulin (BTC), epider-
mal growth factor (EGF), and transforming growth factor-a (TGF-a).
Alignment of the mature forms (that is, after cleavage of the transmem-
brane form) of the five members of the EGF family with the N-terminal
end of EGF (human sequences). The heparin-binding domain of HB-EGF
(underlined), which is rich in the basic amino acid residues, arginine (R)
and lysine (K), is seen to extend into the EGF-like domain and to include
the first conserved cysteine (C) residue. The first two of the six conserved
cysteine residues are shown in bold. HB-EGF and AR are strongly
heparin-binding, BTC is a very weak binder, and EGF and TGF-a do not
bind. Single letter amino acid code.
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teflon homogenizer. Homogenates were centrifuged (14,000 rpm,
5 min, 4°C) in a microcentrifuge to remove nuclei and the
superntatant centrifuged in an ultracentrifuge (50,000 rpm, 60
min, 4°C) to remove cell membranes. Protein concentrations were
determined using the Lowry method. Mesangial cell lysates and
rat kidney cytoplasmic fractions (boiled in SDS-PAGE sample
buffer so that approximately 40 mg of protein was added per well
on the final gel) were run on 12.5% SDS-PAGE gels together with
low molecular weight markers (Rainbow; Amersham PLC) at 160
volts/30 mAmp for two hours, using the Bo-Rad Minigel apparatus
Fig. 2. In situ hybridization for HB-EGF mRNA. Expression of HB-EGF mRNA in normal and abnormal glomeruli using in situ hybridization. The
panels are: (A) sense riboprobe used to stain day 17 PHN kidney. No staining was seen in the kidney. (B) Normal kidney. There is very faint staining
within occasional GEC (arrowhead). (C) PHN, day 7. Staining is present within the cytoplasm of GEC (arrowhead), as well as some tubules (arrow).
(D) PHN, day 17. Increased staining within GEC (arrowhead), cells of Bowman’s capsule (double arrowhead), and tubules (arrow). (E) PAN, day 2.
Staining is present within GEC (arrowhead), Bowman’s capsule, and tubules (arrow). (F) PAN, day 21. Staining within GEC (arrowhead). Staining is
also seen in tubules (arrow), and cells of Bowman’s capsule (double arrow). (All original magnifications 3150. Abbreviations are in the Appendix).
Publication of this figure in color was made possible, in part, by a grant from Roche Products Pty Ltd., Dee Why, New South Wales, Australia.
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and then transferred to nitrocellulose membranes. The blots were
blocked with 3% skim milk (SM) in Tris-buffered saline with 0.1%
Tween (TBST) for 60 minutes. The blots were then incubated with
rabbit anti-HB-EGF antibodies (R847 at 2 mg/ml; R866 diluted
1:1,000) in 3% SM/TBST for 60 minutes before washing and
incubation with horseradish peroxidase linked Protein A (Amersham
PLC) diluted 1:500 in 3% SM/TBST for 30 minutes. The blots were
then incubated with ECL reagents (Amersham PLC) and exposed on
X-ray film. Normal rabbit serum or purified rabbit Ig (Sigma) were
used as negative controls. For Western blots using recombinant
human growth factors, EGF (Sigma), TGF-a (Sigma), betacellulin
(R&D Systems), amphiregulin (R&D Systems), and HB-EGF
(R&D Systems) were boiled in SDS-PAGE sample buffer (reducing)
and 200 ng per well loaded onto each gel. The blots were then probed
with R866, R847 or control antibody as outlined above.
Immunohistochemical staining
Tissue blocks were immersion fixed in 4% paraformaldehyde
and embedded in paraffin. Four-micrometer thick paraffin sec-
tions were cut on a microtome and dried overnight at 37°C. A
variety of incubation times, antibody dilutions, blocking solutions
and enzyme treatments were tested before optimal staining was
obtained. Experimental pretreatments used included microwav-
ing, or incubation with enzymes such as pronase E, proteinase K,
hyaluronidase, proteinase VIII, and proteinase XXIV (all from
Sigma). The following protocol produced optimal staining and
was ultimately adopted; sections were dewaxed and treated with
0.1% pronase E (Sigma) for six minutes at 37°C. Endogenous
peroxidase activity was inhibited using 3% hydrogen peroxide for
10 minutes. Sections were then blocked with sheep serum (Gibco)
for 30 minutes, and incubated overnight at 4°C with rabbit
anti-HB-EGF antibody, either R847 at 10 mg/ml or R866 diluted
1/250. Negative controls used were normal rabbit immunoglobulin
(Ig; Dako Corporation, Carpinteria, CA, USA) diluted 10 mg/ml
or diluted normal rabbit serum. Rabbit Ig was detected using a
triple layer technique, comprising monoclonal mouse anti-rabbit
Ig diluted 1/50 (Dako) followed by biotinylated sheep anti-mouse
Ig diluted 1/200 (Amersham, Life Sciences, Buckinghamshire,
UK) and streptavidin-conjugated horseradish peroxidase (Dako)
diluted 1/300, each for 30 minutes, with washing steps between
incubations. Sections were developed using nickel-enhanced dia-
minobenzidene (Pierce, Rockford, IL, USA) and counterstained
with hematoxylin. Staining obtained with cryopreserved and mer-
curic chloride-fixed sections was inferior to that observed in
sections stained by the method outlined above.
Localization of tubular staining using tubular markers
To determine the location of tubular staining seen with anti-
HB-EGF antibodies, sequential sections were stained with tubular
markers [24]. The fluorescein-labeled lectin Arachis hypogea
(AH; Sigma) was used to identify distal convoluted tubules (DCT)
and collecting ducts while Phaseolus vulgaris erythroagglutinin
(PHA-E) was used for cells of the proximal convoluted tubule
(PCT). Lectin binding was identified using immunoperoxidase-
conjugated anti-FITC Fab fragments (Boehringer Mannheim,
Mannheim, Germany), followed by diaminobenzidine and hema-
toxylin as described earlier. Rabbit anti-Tamm-Horsfall protein
(THP) antibody (gift of Dr. H.Y. Lan, Monash Medical Centre,
Clayton, Victoria, Australia) was used to identify cortical and
medullary thick ascending limbs of the loop of Henle (TAL). The
staining method used was identical to that for HB-EGF.
Fig. 3. Western blot of solubilized rat glomerular mesangial cells probed
with anti-HB-EGF antibodies R847 and R866. In these blots, the trans-
membrane form of HB-EGF has a molecular size of approximately 27
kDa, whereas the expected size of the secreted form is approximately 21
kDa. Western blots A and B show anti-HB-EGF antiserum (R866), or
antibody (R847), normal rabbit serum (NRS) or normal rabbit immuno-
globulin (NRIg) against rat kidney and cultured rat mesangial cell lysates,
respectively. With both antibody preparations, predominant reactivity is
seen with a 29 kDa species, consistent with the transmembrane form of
HB-EGF. There is no band consistent with the secreted form. In Western
blot C, R847 is blotted against recombinant human HB-EGF (lane 1),
amphiregulin (lane 2), betacellulin (lane 3), EGF (lane 4), TGF-a (lane
5), and BSA (lane 6). A strong band at about 19 to 23 kDa is seen in the
lane loaded with HB-EGF. An identical Western blot probed with normal
rabbit immunoglobulin (NRIg) shows no band. R866 did not blot human
HB-EGF.
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In situ hybridization
A rat HB-EGF cDNA probe corresponding to positions 231-
254 and 707-726, respectively, in the published sequence of rat
cDNA [22], was produced by polymerase chain reaction (PCR)
amplification, as previously described [17]. Primers were selected
to include the sequence encoding the mature HB-EGF protein.
This 495 bp cDNA fragment was subcloned into the multiple
cloning site of the plasmid pGEM-T (Promega, Madison, USA)
between the SP6 and T7 promoters. The insert was sequenced
over its full length on both strands and found to be identical to the
published sequence of rat HB-EGF.
pGEM-T containing the HB-EGF cDNA fragment was linear-
ized with the restriction enzymes SacII (sense probe) or Spe I
(anti-sense probe). Labeled riboprobes were synthesized using T7
RNA polymerase (anti-sense probe) or SP6 RNA polymerase
(sense probe) incorporating digoxigenin-labeled uridine-triphos-
phate (Boehringer Mannheim). The anti-sense riboprobe but not
the sense riboprobe detected a 2.5 kb transcript on a Northern
Fig. 4. Immunohistochemical localization of HB-EGF in normal kidney.
(A) Section of the inner (IM) and outer medulla (OM) stained with
anti-HB-EGF antibody R866. Strong HB-EGF immunoreactivity is seen
in the thick ascending limbs of the loop of Henle (TAL) (original
magnification 315.2). (B and C) Section of cortex stained with R866 (B)
and the next sequential section stained with a rabbit anti-THP antibody
(C) to identify the TAL. There is near complete correspondence of
staining; one tubular cross section is marked in both Figures for orienta-
tion (large arrowhead) (original magnifications 375). (D and E) Section of
cortex stained with R866 (D) and the next sequential section stained with
the lectin Arachis hypogea (AH) to identify distal convoluted tubules and
collecting tubules (E). A tubule stained with AH but not R866 is shown
(star), as well as a tubule that stained with both (arrow). Tubules that
stained with R866 and AH were mainly DCT, based upon the size of the
tubular cell (original magnifications 375).
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blot of mesangial cell RNA. Paraffin sections were cut 4 mM thick.
Sections were dewaxed and dehydrated in alcohol, treated with 0.2
M HCl for 20 minutes, rinsed with DEPC water 32 for five
minutes then placed in 2 3 SSC 70°C for 10 minutes and rinsed in
DEPC water. Digestion of sections was undertaken with 20 mg/ml
proteinase K (Sigma) in 100 mM Tris-HCl pH 8.0/50 mM EDTA at
37°C for 30 minutes. Digestion was stopped by immersion in 2
mg/ml glycine in PBS. Slides were rinsed in PBS 32 and fixed in
4% paraformaldehyde for 15 minutes, rinsed with PBS and
equilibrated with 100 mM triethanolamine pH 8.0. Acetic anhy-
dride was added to block positively charged groups that might
bind the probe. Sections were prehybridized in hybridization
buffer [50% formamide, 35 SSC, 2% block reagent (Boehringer
Mannheim), 0.02% SDS, 0.1% N-lauroylsarcosine] for 60 minutes
at 37°C and then hybridized overnight with denatured DIG-
labeled sense and antisense riboprobe at a concentration of 150
ng/ml in a humidified chamber at 42°C. After treatment of the
slides with DNase-free RNase A (5 mg/ml) for 30 minutes at 37°C,
colorimetric detection of mRNA following hybridization was
accomplished with the non-radioactive nucleic acid detection kit
(Boehringer Mannheim) following the manufacturer’s instruc-
tions. Sections were counterstained with Nuclear Fast Red. Tissue
obtained from each of three rats was stained and examined at
each time point.
Preparation of glomerular membrane protein fractions
Glomeruli were isolated from kidneys obtained from controls
and rats at days 5 and 14 for the PAN model and at days 5 and 21
for the PHN model (N 5 3, at each time point). Subcellular
fractions were prepared as described by Egerton et al [25] with
minor modifications. All steps were performed at 4°C. Briefly,
glomeruli were isolated as outlined above and sonicated at 3 3 10
seconds at 20% setting using a Branson sonifier (Branson Ultra-
sonics, USA). NaCl was restored to 150 mM using 0.11 volumes of
1.5 M NaCl and the lysate centrifuged at 700 g for seven minutes
to pellet nuclei. The post-nuclear supernatant was reconstituted to
5 mM EDTA and centrifuged at 100,000 g for 60 minutes to
separate the soluble fraction (cytosol) from the insoluble pellet
(membranes and cytoskeleton). The pellet was then solubilized in
mammalian cell lysis buffer (50 mM Tris-HCl pH 7.4; 150 mM
NaCl; 5 mM EDTA; 0.5% Triton X-100) and centrifuged at 12,000
g for 15 minutes to separate the soluble supernatant (membranes)
from the pellet (cytoskeleton). All samples were stored at 270°C
until used. For Western blots, 5 mg of protein was added to each
lane of a 12.5% gel.
For detection of HB-EGF protein by Western blot, protein
concentrations were determined by a commercial Bradford assay
(BioRad Protein Assay). Equal quantities of protein (5 mg per
well) were loaded onto 12.5% SDS-PAGE gels, then blotted and
probed with R847 as outlined earlier. Results were quantitated by
laser densitometry using a Molecular Dynamics Computing Den-
sitometer, Model 300A and ImageQuant Software (version 3.0).
RESULTS
mRNA transcripts detected by in situ hybridization
Sense controls were negative (Fig. 2A), apart from occasional
nonspecific staining around the edge of the section. HB-EGF
mRNA transcripts were faintly detectable by in situ hybridization
in occasional tubules and visceral GEC of normal rat kidney (Fig.
2B). In the PHN model, increased HB-EGF mRNA was detected
by in situ hybridization at day 3 after the first injection of
anti-Fx1A and continued until day 21 (Fig. 2 C, D). Expression by
parietal and visceral GEC was markedly increased in the PAN
model at days 1 and 3 post-induction, continuing until day 21 (Fig.
2 E, F). In both models, there was a slight but widespread increase
in expression by tubular cells. There was no clear increase in
expression by vascular endothelial cells or smooth muscle cells of
the vascular media.
Validation of anti-HB-EGF antibodies using Western blots
To determine whether anti-HB-EGF antibodies detected rat
HB-EGF, unfractionated rat whole kidney (Fig. 3A) and mesan-
gial cell (Fig. 3B) lysates were blotted onto nitrocellulose and
probed with R847 and R866. Both antibodies detected a band of
27 to 29 kDa, consistent with the transmembrane form of HB-
EGF (Fig. 3 A, B). In addition, R847 detected a 19 to 23 kDa
species when blotted against recombinant human HB-EGF (Fig.
3C) but not the related growth factors amphiregulin, betacellulin,
EGF, and TGF-a. R866 did not react in Western blots with any of
the human growth factors (data not shown).
Immunohistochemical staining with rabbit anti-HB-EGF
antibodies
Paraformaldehyde-fixed, enzyme-treated sections were stained
with negative control antibody or with one of the anti-HB-EGF
antibodies, R847 or R866. Sections stained with negative control
antibody showed no staining. In normal kidney, there was impres-
sive tubular expression in the outer medulla that was localized
predominantly to TAL (Fig. 4A). In the cortex, expression
occurred mainly in cortical TAL (Fig. 4 B, C) and DCT (Fig. 4 D,
E). Staining occurred mainly at the basolateral surface of these
cells. Epithelial cells of the transitional epithelium in the papillary
area, as well as smooth muscle cells and endothelium of medium-
sized arteries and arterioles were also positive. There was also
weaker staining in the microvillous border of cortical PCT, and
occasional visceral and parietal glomerular epithelial cells. Stain-
ing in the microvillous border of cortical PCT was not always seen
and appeared more intense in some of the disease models (see
below).
In the disease models, negative controls showed no staining
(Fig. 5A). Normal glomeruli were usually negative (Fig. 5B),
although occasional GEC were weakly positive in some sections.
Following induction of either of the two models, there was
increased staining for HB-EGF within GEC (Fig. 5 C-H); staining
for immunoreactive HB-EGF occurred within three days in both
models in visceral GEC (Fig. 5C). Staining gradually became
more intense (Fig. 5E) until, by day 21, there was clear expression
in GEC in both models with small immunoreactive “nodules” and
areas of apparent linear staining, some of it forming double
contours (Fig. 5 D, F-H). The precise location of the small
“nodules” was not clear but they occurred in both PAN and PHN
models. Staining with a second anti-HB-EGF antibody, R847, was
very similar to that seen with R866 (Fig. 5 G, H), although there
was greater background staining with R847. In some of the disease
sections, immunoreactivity in the brush border of cortical PCT
and the luminal surface of distal tubules appeared greater than in
control sections (for example, Fig. 5F compared with 5B).
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Detection of HB-EGF in glomerular protein fractions by
Western blot
A single species of approximately 29 kDa was detected in
normal glomeruli and this increased two to three times in the
models (Fig. 6). There was no increase in the disease models
between day 5 and the later days studied, and no other species was
detected. Western blots of cytoplasmic protein showed no detect-
able HB-EGF (data not shown).
DISCUSSION
In the PHN and PAN models of proteinuria, in situ hybridiza-
tion showed up-regulated expression of HB-EGF mRNA within
GEC prior to the onset of proteinuria. This continued through to
day 21 in both models. Immunohistochemical staining for HB-
EGF also increased during the course of both models. Within the
glomerulus, staining was initially confined to the body of glomer-
ular epithelial cells within the glomerulus and occurred within
three days in both models, following the pattern of increased
HB-EGF mRNA determined by in situ hybridization. There were
occasional areas of apparent linear staining, even at the early time
points. By days 17 to 21, however, this was markedly increased
with apparent membrane staining in some areas. Some of the
staining within the GEC also appeared to be nodular.
The increase in HB-EGF protein was confirmed by Western
blots of membrane protein fractions from isolated glomeruli.
These showed a two- to threefold increase in a 29 kDa protein,
consistent with the transmembrane form of HB-EGF [26]. Lower
molecular mass bands that might be consistent with the secreted
form were not detected. The cell-associated form of HB-EGF is
able to signal in a paracrine manner [26] and GEC have been
reported to possess the EGF receptor [27]. Therefore, this finding
suggests that any contribution of HB-EGF to the genesis of
proteinuria is likely to be as a mitogenic factor. However, it is also
possible that the secreted form of HB-EGF binds to the GBM,
which might be relatively poorly solubilized compared with other
membrane fractions. This issue can only be resolved by Western
blots of isolated GBM preparations or immunogold electron
microscopy to accurately localize the increase in HB-EGF; these
studies are currently in progress.
Synthesis of the mRNA or protein for a number of extracellular
matrix molecules is increased in experimental membranous ne-
phropathy [28]. This is the second growth factor reported to be
up-regulated by GEC in PHN. Floege et al [29] found that PDGF
protein and mRNA was increased in visceral GEC at day 3 after
induction of PHN, but declined therafter. In contrast, the present
studies have shown that HB-EGF mRNA and protein become
clearly increased at day 3 after induction and continue to increase
until day 21, the last time point studied. Floege et al have also
reported that a receptor for FGF-2 (flg) is present within the
immune deposits along the epithelial side of the GBM in Hey-
mann nephritis and that the receptor is up-regulated in GEC [30].
FGF-2 synthesis, however, was not increased in the model. In
human membranous glomerulonephritis, a disease closely related
to PHN, tumor necrosis factor-a (TNF-a) is clearly up-regulated
within GEC [31], but this observation has not yet been made in
PHN. There are no data demonstrating up-regulated heparin-
binding growth factor expression by GEC in acute PAN, although
alterations in interleukin 1 (IL-1) and TNF have been reported in
the acute phase [32–34], and changes in various growth factors in
Fig. 6. Western blot of membrane preparations from normal and dis-
eased glomeruli. (A) Western blot of membrane fractions from normal
(lanes 1 and 2), day 5 PAN (lane 3), day 14 PAN (lane 4), day 5 PHN (lane
5), and day 21 PHN (lane 6). A single species of approximately 29 kDa was
detected. (B) Densitometric analysis of the Western blot showing approx-
imately a two to three times increase in the intensity of the 29 kDa band.
This blot was performed twice, with similar results.
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Fig. 5. Immunohistochemical staining for HB-EGF in normal and abnormal glomeruli. All sections were stained with the rabbit anti-HB-EGF
antibody R866, except for the negative control (stained with normal rabbit serum at the same dilution as R866), and panels G and H, which were stained
with R847. The panels are: (A) negative control performed using tissue from a rat with PHN, day 17. (B) Glomerulus from normal rat. Strong staining
is seen in some tubules (star) and weakly in the brush border of some PCT (arrow). (C) PAN, day 2. Staining is seen within the glomerulus, mainly within
GEC (arrowhead). There is no obvious change in the intensity of staining with the glomerulus. (D) PAN, day 21. A positive GEC (arrowhead) and an
area with nodular staining (arrow) are shown. (E) PHN, day 7. There is increased staining within the glomerulus compared with normal, mainly in GEC
(arrowhead). (F) PHN, day 21. Staining is similar to that seen with PAN at day 21. Staining is seen in GEC (arrowhead) and as a double contour along
the GBM (arrow). There are several areas where the staining is nodular. (G) PAN, day 21. Section stained with R847. Similar collections of
immunoreactive material can be seen in some GEC with staining in distal tubular and PCT cells. (H) PHN, day 21. Section stained with R847. Similar
collections of immunoreactive material can be seen in some GEC with staining in distal tubular and PCT cells (all original magnifications 3150).
Publication of this figure in color was made possible by a grant from Janssen-Cilag Pty Ltd., Lane Cove, New South Wales, Australia.
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a model of focal glomerular sclerosis have been reported at later
time points [35].
This study also describes the distribution of immunoreactive
HB-EGF in normal kidney. The staining pattern differs from that
described in two other publications. Nakagawa et al [36] reported
predominant expression of HB-EGF protein in the S3 segment of
the proximal tubule, as well as other proximal tubular cells and
arterial smooth muscle. By contrast, Sakai et al [37] found
immunoreactive HB-EGF in intralobular arteries and occasional
cortical collecting duct cells, but no expression in the inner or
outer medullas. Both groups reported no expression of HB-EGF
protein in normal glomeruli [36, 37]. In the present studies,
HB-EGF protein was found in isolated glomeruli by Western blot,
and mRNA transcripts by both RT-PCR and Northern blots (data
not shown). Histochemical staining for HB-EGF was negative in
normal glomeruli. Within tubules, prominent expression of HB-
EGF protein was found in TAL in the outer medulla as well as
DCT. This pattern of expression is similar to that reported by
Sakai et al in kidneys subjected to ischemia-reperfusion injury
[37]. The differences may be due to the use of enzymatic
treatment, in the present study, to reveal “hidden” epitopes.
Without prior enzymatic treatment, the staining pattern observed
was similar to that reported by Sakai et al [37] in normal rat
kidney (data not shown). These data suggest a much more
extensive distribution of HB-EGF in normal rat kidney than has
previously been suggested. The protein was also localized to the
basolateral surface of tubules, suggesting that it might stimulate
the EGF receptor that is also located on the basolateral surface of
tubular epithelium [38].
In summary, this study has shown that HB-EGF mRNA and
protein is up-regulated by GEC in two models of heavy protein-
uria. Most of the increase appeared to be in a 29 kDa species,
which is compatible with the transmembrane form. These studies
suggest that the increase in HB-EGF is cell-associated and that
HB-EGF may, therefore, stimulate mitogenesis in a juxtacrine
fashion. Further studies are required, however, to determine
whether the secreted form is present along the GBM.
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APPENDIX
Abbreviations used in this article are: AH, Arachis hypogea; DCT,
distal convoluted tubule; EGF, epidermal growth factor; GBM, glomeru-
lar basement membrane; GEC, glomerular epithelial cells; FGF-1 and
FGF-2, fibroblast growth factors; HB-EGF, heparin binding-epidermal
growth factor-like growth factor; HSPG, heparan sulfate proteoglycans;
Ig, immunoglobulin; IL-1, interleukin 1; KLH, keyhole limpet hemocya-
nin; OVA, ovalbumin; PAN, puroaminonucleoside; PCR, polymerase
chain reaction; PCT, proximal convoluted tubule; PHN, passive Heymann
nephritis; rHB-EGF69-92, residues 69-92 of rat heparin binding-epidermal
growth factor-like growth factor; SM, skim milk; TAL, thick ascending
limb of the loop of Henle; TBST, Tris buffered saline with 0.1% Tween;
TGF-a, transforming growth factor alpha; THP, Tamm-Horsfall protein;
TNF-a, tumor necrosis factor-a.
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